Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7946425 | 0.89 | KDM4E (0.49) | CYP11B2MEN1KMT2AMKNK1MKNK2 | |
| SCHEMBL7954909 | 0.87 | MKNK1 (0.41) | CYP11B2MEN1KMT2ACSNK1DCSNK1E | |
| SCHEMBL7585895 | 0.86 | KMT2A (0.56) | CYP11B2MEN1KMT2AKDM4ELMNA | |
| SCHEMBL7960330 | 0.86 | MKNK1 (0.40) | CYP11B2MEN1KMT2ACSNK1DCSNK1E | |
| SCHEMBL7957167 | 0.86 | MKNK1 (0.40) | CYP11B2MEN1KMT2ACSNK1DCSNK1E | |
| SCHEMBL895772 | 0.86 | MKNK1 (0.41) | CYP11B2MEN1KMT2ACSNK1DCSNK1E | |
| SCHEMBL7953707 | 0.85 | KDM4E (0.46) | CYP11B2MEN1KMT2ACSNK1DCSNK1E | |
| SCHEMBL7953523 | 0.85 | KMT2A (0.44) | CYP11B2MEN1KMT2ACSNK1DCSNK1E | |
| SCHEMBL7954819 | 0.85 | KDM4E (0.42) | CYP11B2MEN1KMT2ACSNK1DCSNK1E | |
| SCHEMBL7955729 | 0.84 | CSNK1D (0.38) | CYP11B2MEN1KMT2ACSNK1DCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | claimed |
| US-20110184011-A1 | Compounds | SELCIA LIMITED (GB) | 2011-07-28 | — | — | US | disclosed |
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184011-A1 | Compounds | COL1A1, ALDH1A2, COL2A1 | CYP11B2 164/4885MEN1 2252/4885KMT2A 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.